Advertisement

Serotonin Syndrome: When the Happy Hormone Gets Angry

  • Greg EisingerEmail author
  • Mena Botros
  • Lauren Branditz
Chapter

Abstract

Serotonin syndrome is a life-threatening condition caused by iatrogenic overactivation of 5HT1a and 5HT2a receptors characterized by the triad of encephalopathy, dysautonomia, and neuromuscular abnormalities. Although certain narcotics have been implicated, case reports related to fentanyl are scarce and the entire drug class is likely under-recognized as a potential precipitant in the clinical setting. We describe a postoperative patient who developed moderately severe serotonin syndrome while receiving a high-dose fentanyl infusion in the context of outpatient paroxetine therapy. The case was successfully managed by the withdrawal of the offending agents and treatment with cyproheptadine. We present a summary of the pathophysiology, diagnosis, and management of the serotonin syndrome.

Keywords

Serotonin syndrome Fentanyl Opioids Toxicology Drug reactions Critical care 

Notes

Disclosure Statement

The authors of this chapter report no significant disclosures.

References

  1. 1.
    Volpi-abadie J, Kaye AM, Kaye AD. Serotonin syndrome. The Ochsner Journal. 2013;13(4):533–40.Google Scholar
  2. 2.
    Boyer EW, Shannon M. Current concepts: the serotonin syndrome. N Engl J Med. 2005;352(11):1112–20.CrossRefGoogle Scholar
  3. 3.
    Gummin D, Mowry J, Spyker D, Brooks D, Fraser M, Banner W. 2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report. Clin Toxicol. 2017;55(10):1072–254.CrossRefGoogle Scholar
  4. 4.
    Asch DA, Parker RM. The Libby Zion case. One step forward or two steps backward? N Engl J Med. 1988;318(12):771–5.CrossRefGoogle Scholar
  5. 5.
    Trevor AJ, Katzung BG, Kruidering-Hall M, Trevor AJ, Katzung BG, Kruidering-Hall M. Antidepressants. In: Trevor AJ, et al., editors. Katzung & trevor’s pharmacology: examination & board review. 11th ed. New York, NY: McGraw-Hill; 2015. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1568&sectionid=95702844. Accessed 17 Sep 2019.
  6. 6.
    Isbister GK, N a B. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28(5):205–14.CrossRefGoogle Scholar
  7. 7.
    Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007;152(6):946–51.CrossRefGoogle Scholar
  8. 8.
    Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician. 2015;18(10):395–400.PubMedGoogle Scholar
  9. 9.
    Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434–41.CrossRefGoogle Scholar
  10. 10.
    Tao R, Auerbach SB. GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther. 2002;303(2):704–10.CrossRefGoogle Scholar
  11. 11.
    Rickli A, Liakoni E, Hoener MCLM. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532–43.CrossRefGoogle Scholar
  12. 12.
    Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–70.PubMedGoogle Scholar
  13. 13.
    Jhun P, Bright A, Herbert M. Serotonin syndrome and opioids--what’s the deal? Ann Emerg Med. 2015;65(4):434–5.CrossRefGoogle Scholar
  14. 14.
    S. S, C.O. H, S. W, W. W. Serotonin syndrome precipitated by sertraline and discontinuation of clozapine. Clin Toxicol. 2015;53(8):840–1.CrossRefGoogle Scholar
  15. 15.
    Robles L. Serotonin syndrome induced by fentanyl in a child: case report. Clin Neuropharmacol. 2015;38(5):206–8.CrossRefGoogle Scholar
  16. 16.
    Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM – Mon J Assoc Physicians. 2003;96(9):635–42.CrossRefGoogle Scholar
  17. 17.
    Kolecki P. Venlafaxine induced serotonin syndrome occurring after abstinence from phenelzine for more than two weeks. Toxicol Clin Toxicol. 1997;35:211–2.CrossRefGoogle Scholar
  18. 18.
    McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother. 2001;35(7–8):870–3.CrossRefGoogle Scholar
  19. 19.
    Graudins A, Stearman A, Chan B, Kulig K. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Emergency MedicineWexner Medical Center at The Ohio State UniversityColumbusUSA
  2. 2.Department of Pediatrics – Nationwide Children’s HospitalColumbusUSA

Personalised recommendations